"C. albicans malate dehydrogenase (Mdh1p) was identified by the time-course proteome studies discussed above as the group 4 and was thought to be a candidate for a vaccine against candidiasis because it was identified through every periods without large variation in relative abundance. Indeed, Mdh1p was also identified in a proteome study for screening C. albicans immunogenic proteins by a two-dimensional electrophoresis 2-DE) /MS system. As an antigen candidate of C. albicans, a commonly existing protein in every situations and associated with an important metabolic pathway is thought to be suitable for a vaccine. Mdh1p is associated in the citrate cycle. Therefore, recombinant Mdh1 protein with a His-tag was produced in E. coliand evaluated as an immunogenic protein and a candidate vaccine against candidiasis.
OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals with the support of 50,000+ editorial board members as editorial team and aimed to disseminate the scholarly knowledge to the scientific society. OMICS Group also organizing 3000+ International Scientific Conferences and events yearly all over the world with the support of 1000+ Scientific associations worldwide.
Citation: Shibasaki S, Karasaki M, Ueda M (2014) Combining Proteomic Strategies and Molecular Display Technology for Development of Vaccines against Candida albicans. J Proteomics Bioinform 7: 134-138."
Last date updated on July, 2014
